1. Anti-PEG antibodies: We have generated many anti-PEG monoclonal antibodies that can be used for clinical studies of PEGylated medicines. We have also created humanized anti-PEG reference standards for accurate measurment of anti-PEG antibodies in patients. More information is available on the anti-PEG website .
2. Impact of anti-PEG antibodies: Many normal individuals have antibodies against polyethylene glycol (PEG) in their blood. We are investigating how these antibodies affect the efficacy and safety of PEGylated medicines such as methoxy polyethylene glycol epoetin beta for the treatment of anaemia, peginterferon alfa-2a for the treatment of hepatitis B and C, and pegylated liposomal doxorubicin, a liposome nanomedicine used for the treatment of cancer.
3. Antibody engineering: We are engineering immunoconjugates and bispecific antibodies for enhanced drug delivery and improved cancer therapy. We recently developed PEG engagers, which can target PEG-modified nanomedicines to cellular targets such as cancer cells.
4. Prodrug therapy: We are developing anticancer prodrugs that can be selectively activated in the tumor microenvironment. The mechanisms of selective prodrug activation and strategies to improve selectivity are under investigation.
5. Directed molecular evolution: We have developed a powerful screening methodology to identify mammalian (human) enzymes with altered properties by directed molecular evolution. We are employing this technology to improve the properties of proteins for antibody-directed enzyme prodrug therapy and to treat genetic diseases.
6. Glycosidic Switch Liposomes: We have developed a a new type of liposome that can stably retain very potent anticancer medicines. These nanoliposomes are under investigation fro the treatment of pancreatic and metastatic colon cancers
Our publications are available at Roffler Publications